TAXUS LIBERTE PACLITAXEL ELUTING STENT
Report
- Report Number
- 6000089-2006-01584
- Event Type
- Death
- Date Received
- August 2, 2006
- Date of Event
- January 13, 2006
- Report Date
- July 6, 2006
- Manufacturer
- BOSTON SCIENTIFIC CORP.
- Product Code
- NIQ
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- AM
- Reporter Occupation
- PHYSICIAN
Narratives
THE COMPLAINANT INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE, A FAILURE ANALYSIS IS NOT AVAILABLE, AND WE ARE NOT ABLE TO DETERMINE THE ROOT CAUSE OF THIS EVENT. SHOULD FURTHER RELEVANT INFORMATION BECOME AVAILABLE; A SUPPLEMENTAL MEDWATCH REPORT WILL BE FILED.
CLINICAL STUDY, IT WAS REPORTED THAT 6 DAYS AFTER A CORONARY ARTERY DRUG ELUTING STENTING TREATMENT PROCEDURE, THE PATIENT EXPIRED. EIGHT DAYS PRE-PROCEDURE, THE PATIENT WAS ADMITTED TO THE HOSPITAL; CARDIAC ENZYMES INDICATED AN EVOLVING MYOCARDIAL INFARCTION. THE INDEX PROCEDURE TREATED 1 DE NOVO TARGET LESION. THE TARGET LESION WAS A 3.5MM VESSEL DIAMETER, 9MM LONG, WITH NO CALCIFICATION, AND 90% STENOSIS, IN THE PROXIMAL LEFT ANTERIOR DESCENDING (LAD) ARTERY. THE LESION WAS PREDILATED WITH AN INVATEC 1.25X20MM BALLOON. THE PHYSICIAN IMPLANTED 1 TAXUS LIBERETE 3.5X12MM DRUG ELUTING STENT (DES) AT 16 ATMS. POST-TREATMENT, THE LESIONS WERE 0% STENOSIS AND TIMI 3 FLOW. THE PATIENT EXPIRED 6 DAYS POST INDEX PROCEDURE, PRIOR TO DISCHARGE. GASTRO INTESTINAL BLEEDING WAS INDICATED AS THE CAUSE OF DEATH. THE PATIENT WAS RECEIVING ASPIRIN AND PLAVIX. THE DEATH, AS INDICATED BY THE PHYSICIAN, WAS UNRELATED TO THE TAXUS LIBERTE STENT. THIS PRODUCT IS ONLY OUS APPROVED, BUT IT IS SIMILAR TO A MARKETED US DEVICE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | TAXUS LIBERTE PACLITAXEL ELUTING STENT | DRUG ELUTING STENT | NIQ | BOSTON SCIENTIFIC CORP. | 3.5X12MM | 8078002 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 80 YR | Death |